Internal Medicine, Hematology & Oncology · Seattle, WA
NPI
1366648297
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1221 Madison St Ste 1020
Seattle, WA, 98104
Phone (206) 215-2658
Groups this clinician bills Medicare through
Medicare paid, 2024
$36K
446 services
Medicare patients, 2024
150
Average age 73
Drug cost, 2024
$5.9M
1,408 prescriptions
Company payments, 2025
$146
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel N Egan was code 99214 (office e&m - established), 229 times for 96 patients. In total Daniel N Egan billed 446 services in 18 codes, and Medicare paid $36K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 229 | 96 | $72.22 | $17K |
| 99215 Office E&M - Established | Facility | 81 | 48 | $122.12 | $9,892 |
| 99213 Office E&M - Established | Facility | 46 | 32 | $49.69 | $2,286 |
| 99205 Office E&M - New | Facility | 13 | 13 | $152.72 | $1,985 |
| 99204 Office E&M - New | Facility | 12 | 12 | $93.97 | $1,128 |
By year: 2022 $34K for 347 services; 2023 $42K for 483 services; 2024 $36K for 446 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel N Egan prescribed most often to Medicare patients was Acyclovir, with 163 prescriptions and refills. In total Daniel N Egan wrote 1,408 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 163 | 234 | 34 | $2,527 |
| Hydroxyurea Generic | 59 | 106 | 14 | $1,084 |
| Jakafi Ruxolitinib Phosphate | 57 | 57 | Under 11 | $781K |
| Eliquis Apixaban | 54 | 74 | 13 | $42K |
| Revlimid Lenalidomide | 52 | 52 | Under 11 | $1.1M |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 38 | 52 | Under 11 | $328 |
| Gabapentin Generic | 35 | 47 | Under 11 | $872 |
| Venclexta Venetoclax | 35 | 37 | 11 | $129K |
| Onureg Azacitidine | 32 | 32 | Under 11 | $758K |
| Posaconazole Generic | 32 | 32 | Under 11 | $32K |
| Levothyroxine Sodium Generic | 28 | 46 | Under 11 | $148 |
| Imatinib Mesylate Generic | 26 | 30 | Under 11 | $2,045 |
| Dexamethasone Generic | 26 | 43 | 12 | $585 |
| Fluconazole Generic | 25 | 28 | Under 11 | $1,332 |
| Besremi Ropeginterferon Alfa-2b-Njft | 24 | 24 | Under 11 | $390K |
Brand drugs: 437 claims; generic drugs: 971 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel N Egan $146 ($146 in general payments such as food, travel and fees) from 8 companies. The largest payer was Ferring Pharmaceuticals Inc. with $105.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.